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Although insulin effectively blocked  hormone-stim- 
ulated glycerol output in adipocytes or phosphorylase 
activation in hepatocytes, the inhibitory effect of in- 
sulin on  cAMP analog-stimulated cells depended  on the 
CAMP analog used. Of the 20 analogs tested in adipo- 
cytes and 13 tested in hepatocytes, the effects of about 
half of them were effectively blocked by insulin, 
whereas the effects of many of them were not inhibited 
at all. In  order  to approach the explanation for  this 
discriminative insulin action, the inhibitory effects of 
insulin on the responses to  the analogs in  the  intact 
cells were correlated with the in  vitro cAMP analog 
specificity for  the hepatocyte CAMP-dependent protein 
kinase isozymes and the low K,, hormone-sensitive 
phosphodiesterases from both cell  types. No correlation 
was found  between insulin resistance of analog-stim- 
ulated hepatocyte phosphorylase and  the concentration 
of analog required in  vitro for half-maximal activation 
of either type I or type I1 CAMP-dependent protein 
kinase from hepatocytes.  However, a good correlation 
was found  between insulin resistance of  cAMP analog- 
stimulated responses and  the analog IsO values for  the 
phosphodiesterase from both cell types.  Using a new 
method capable of measuring hydrolysis at low analog 
concentrations, several of those analogs which had 
relatively 1ow;but not high, phosphodiesterase IsO val- 
ues were shown to be directly hydrolyzed  by the low 
K ,  adipocyte phosphodiesterase. The insulin inhibition 
of cell responses  when stimulated by hydrolyzable an- 
alogs, but not  by  poorly hydrolyzable analogs, is best 
explained by insulin stimulation of the low K ,  phos- 
phodiesterases from both  cell  types. 
Lipolysis in adipocytes and glycogenolysis in hepatocytes 
are increased by catabolic hormones which elevate cAMP and 
activate CAMP-dependent protein kinase. In  the presence of 
the anabolic hormone insulin, these effects are partially or 
completely  blocked, but  the mechanism is  not certain. It has 
been demonstrated in a number of laboratories that insulin 
decreases intracellular levels of cAMP in  fat  (1,2)  and  in liver 
(3-7) tissues, particularly when they  are elevated.  Some  evi- 
dence suggests that  this is due to  an inhibition of adenylate 
cyclase (8, 9),  but  this  is  not universally accepted (7, 10-12). 
Alternatively, it has been  proposed that insulin stimulates a 
low K,,, cAMP phosphodiesterase to account for the decrease 
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in cAMP  (13-17), although the physiological  significance of 
this effect is questioned (18). Some investigators have  been 
unable to detect a lowering of cAMP under certain conditions 
of insulin action (19-24). Other possible  mechanisms  include 
increases in phosphoprotein phosphatase(s) (25) and protein 
kinase inhibition (26, 27)  by this hormone. The  latter effect 
would result, in  part, from an inhibition of protein kinase 
activity secondary to a decrease in cAMP  due to phosphodi- 
esterase activation. However, it has been  suggested that in- 
sulin reduces the sensitivity of protein kinase to cAMP and 
thereby inhibits  the enzyme without lowering  CAMP  (28). To 
account for hepatic insulin action, a recent study concluded 
that inhibition of CAMP-dependent protein kinase occurs 
independently of cAMP changes and phosphodiesterase acti- 
vation (23). Several groups  (25,29-31)  have partially purified 
low molecular  weight peptide(s) which  could mediate some or 
all of the effects of insulin. In order to account for the many 
and diverse actions of insulin, it is  not unreasonable to con- 
sider that after insulin binds to the receptor, there  are multiple 
pathways of action. 
A study was recently conducted using cyclic nucleotide 
analogs to stimulate lipolysis in isolated rat adipocytes  (32). 
The pattern of analog effects indicated that they were acting 
through CAMP-dependent protein kinase activation. This 
provided the groundwork  for the present study which  dem- 
onstrates  that, although insulin blocks hormonal effects, it 
does not block the effects of all cAMP  analogs  used to stim- 
ulate adipocyte  glycerol output and hepatocyte phosphorylase. 
In order to examine the reason for the discriminative insulin 
action, both cell types were thoroughly characterized for 
cAMP analog potency and specificity in the presence and 
absence of insulin, .and the specificities of the same cAMP 
analogs were determined for the isolated low K, phospho- 
diesterases and CAMP-dependent protein kinases. These ex- 
periments present a unique approach to the use of cAMP 
analogs to study the mechanism of insulin action on  cyclic 
nucleotide-mediated processes. A preliminary report of these 
findings has previously appeared (33). 
EXPERIMENTAL PROCEDURES 
Adipoqte Experiments-Adipocytes  were isolated by  collagenase 
treatment of rat epididymal fat pads according to the method of 
Rodbell  (34).  All aspects of adipocyte experiments were as previously 
described (32), with some exceptions. Incubations were for 30 min at 
37  “C. Cells were preincubated for 8-12 min in  the presence or absence 
of 1 nM insulin before the addition of hormone or cyclic nucleotide 
analog. There was no effect of insulin on basal lipolytic rates. A 
maximal lipolytic response (10-12 pmol of glycerol/g of fat, dry 
weight/30 min) was determined using 10 p~ epinephrine in the 
presence of 200 p~ isobutylmethylxanthine. Glycerol release was 
determined after 30 min of incubation as a measure of lipolysis 
according to the method of Wieland (35), as previously described 
(32). 
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ase perfusion of rat livers, as described by Blackmore and Exton (36). 
Hepatocyte Experiments-Hepatocytes were prepared by collagen- 
Briefly, hepatocytes were isolated from the livers of  180-220-g rats. 
The livers were perfused in situ at 37 "C with Ca2+-free Krebs- 
Henseleit bicarbonate buffer, pH 7.4, containing 11 mM glucose, 5 
mM sodium pyruvate, 5 mM sodium L-glutamate, and washed human 
erythrocytes (10% hematocrit). After an initial noncirculating flow 
through the liver with the above buffer (50 ml),  a 0.4 mg/ml collagen- 
ase solution (Worthington, type I) was recirculated through the liver 
for 30 min. The cells were shaken away from the digested liver, poured 
through nylon mesh, and centrifuged at  50 X g for 2 min. Cells were 
resuspended in the above buffer containing 1.5% gelatin and prein- 
cubated for 10 min in the presence or absence of 6 nM insulin before 
the addition of a series of concentrations of glucagon or cyclic nu- 
cleotide analog. After a 5-min incubation,  a 500-pl aliquot of the cell 
suspension was removed, frozen in liquid nitrogen, and stored at  
-70 "C until assayed. Pellets were partially thawed, homogenized, 
and assayed for phosphorylase by measuring the incorporation of 
['4C]Glu-1-P into glycogen in  the absence of 5'-AMP, as previously 
described (36). In  the absence of glucagon, there was little or no effect 
of insulin on the basal activity of phosphorylase. A maximal phos- 
phorylase activity (a 3-4-fold activation) was elicited by 10 KIM 
glucagon  (28-32  pmol of Glu-1-P/g, wet weight/min). 
Preparation and Assay of Adipocyte and Hepatocyte Particulate 
Phosphodiesterase-The low K,,, phosphodiesterase from adipocytes 
and hepatocytes were prepared and assayed according to  the modified 
method (31) of Loten  et al. (16). These enzymes have been shown to 
be sensitive to insulin stimulation when the phosphodiesterases are 
partially purified from hormone-treated intact cells (13, 14, 16). 
Consistent with other  reports (13, 14), the concentration of cAMP in 
this study required for half-maximal activity of the enzymes from 
both cell types was between 0.4-0.8 p ~ .  Im values were determined, 
as previously described (32), using a concentration of 0.1 p~ [3H] 
cAMP as substrate  in the  standard phosphodiesterase assay. Cyclic 
nucleotide analogs were added to  the reaction mixture in a wide range 
of concentrations. The value was taken as a measure of analog 
competition for [3H]cAMP hydrolysis and was expressed as the 
concentration of analog which inhibit [3H]cAMP hydrolysis by 50%. 
Determination of Cyclic Nucleotide Analog Hydrolysis-CAMP an- 
alogs were incubated with adipocyte phosphodiesterase at concentra- 
tions equivalent to  their 150 value. After various times of incubation 
(0-45 min), aliquots of the reaction mixture were boiled for 5 min 
and appropriately diluted. The concentration of cAMP analog, a t  
zero time and  at various times following incubation with the phos- 
phodiesterase, was determined using a standard curve for each analog 
in a protein kinase assay. The adipocyte or bovine heart type I1 
protein kinase was used as enzyme and synthetic heptapeptide as 
substrate, as previously described (32, 37). Duplication incubations 
of cAMP analog and phosphodiesterase were carried out on at  least 
three different phosphodiesterase preparations, and  the cAMP analog 
concentration was determined from at  least two different dilutions of 
boiled incubation mixture. 
Apparent K, Determination for Cyclic Nucleotides-The type I and 
type I1 protein kinases from hepatocytes were completely separated 
by DEAE-cellulose column chromatography, as previously described 
(38). The adipocyte type I1 protein kinase was purified in  a similar 
manner, as described in Ref.  37. The  apparent K, values for cAMP 
and cAMP analogs were determined in a standard protein kinase 
assay, using synthetic  heptapeptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly) 
as substrate, as described in Ref. 32. The apparent K, is defined as 
the concentration of cAMP analog required for half-maximal activa- 
tion of the enzyme. Experiments for the hepatocyte enzymes were 
carried out with a total protein kinase activity of  1200-1800 pmol of 
32P incorporated per min/ml of enzyme and a basal activity ratio 
(activity  in the absence divided by activity in the presence of 5 p~ 
CAMP) of  0.10-0.15 for type I and 0.02-0.08 for type 11. Apparent K, 
values for the adipocyte protein kinases were determined as described 
in Ref. 37. The  apparent K. value is expressed as K: which is defined 
as  the ratio of the  apparent K,, for cAMP divided by the apparent K, 
for the cAMP analog. 
Material~-[~~C]Glu-l-P was obtained from ICN. 8-Thioparachlo- 
rophenyl-CAMP was purchased from Boehringer Mannheim. N6- 
Diethyl-, N6-carbamoylpropyl-, 6-thiomethyl-, b-thioparanitroben- 
zyl-, and 2-trifluoromethyl-CAMP were generously provided by Drs. 
Jon Miller and Robert Suva of Biochemical Research Laboratory, 
Life Sciences Division, SRI International, Menlo Park, CA. RO-7- 
2956 was a kind gift from Dr. Peter F. Sorter from Hoffmann- 
LaRoche. Glucagon and insulin were generous gifts from Lilly. Other 
materials were as described in Ref. 32. 
RESULTS 
The Effect of CAMP Analogs  on  Physiological  Responses in 
Adipocytes and Hepatocytes-From the results of recently 
conducted studies using cAMP analogs to stimulate lipolysis 
in isolated rat adipocytes (32) and glycogenolysis in  hepato- 
cytes (39), it was concluded that analogs act by crossing the 
cell membrane to directly activate the CAMP-dependent pro- 
tein kinase. In  the present study, a large number of cAMP 
analogs were tested in both hepatocytes and adipocytes. 
The most interesting feature concerning analog efficacy 
was the striking difference in sensitivity between adipocytes 
and hepatocytes (Table I). Adipocyte lipolysis was sensitive 
to cAMP analogs in the millimolar concentration range, 
whereas hepatocyte phosphorylase was activated in the mi- 
cromolar concentration range. For example, the ECbO (concen- 
tration required for half-maximal activation) for 8-thioethyl- 
cAMP in adipocytes was about 1 mM, whereas the same extent 
of phosphorylase activation in hepatocytes required only 0.3 
PM. Similarly, half-maximal activation of adipocyte lipolysis 
required approximately a 3,000-fold higher concentration of 
8-bromo-CAMP and  a 10,000-fold higher concentration of 8- 
thioparachlorophenyl-CAMP than was required for the same 
extent of hepatocyte phosphorylase activation. Generally, 
hepatocytes were 100-10,000 times more sensitive than adi- 
pocytes to cAMP analog stimulation when comparing these 
two physiological processes. 
Another aspect of analog potency concerned a comparison 
of relative potencies within each cell type. The analogs fol- 
lowed a similar, but not identical, rank order of potency in 
adipocytes and hepatocytes. For analogs modified at  the 8- 
carbon of the adenine ring, 8-thio derivatives were among the 
most potent  agents and were considerably more potent than 
8-amino derivatives in  both cell types (Table I). For example, 
the EC50 for 8-thiomethyl-CAMP was 8- and 12-fold lower 
than  that of 8-aminomethyl-CAMP in hepatocytes and  adi- 
pocytes, respectively. In both cell types, 8-thioethyl- and N6- 
benzoyl-CAMP  were potent agents, N'-butyryl- and 8-bromo- 
cAMP were of intermediate potency while 8-amino derivatives 
were least potent. However, some analogs varied in relative 
potency between the cell types. 8-Thioparachlorophenyl- and 
8-thioparanitrobenzyl-CAMP were the most potent  in hepa- 
tocytes and of intermediate potency in adipocytes. Conversely, 
8-thioisopropyl-CAMP and N6-carbamoylpropyl-CAMP were 
TABLE I 
Potency of CAMP analogs in isolated  cells 
ECso  ECso 
Cyclic  nucleotide  analog  adipocyte  hepatocyte 
lipolysis phosphorylase 
P M  P M  
N6-Carbamoylpropyl-CAMP 500 3.0 
8-Thioisopropyl-CAMP 500 2.0 
N'-Benzoyl-cGMP 700 0.5 
8-Thioethyl-CAMP 900  0.3 
8-Thioparachlorophenyl-CAMP 1,000 0.1 
8-Thiomethyl-CAMP 1,000 0.5 
8-Thioparanitrobenzyl-CAMP 1,200  0.1 
fl-Butyryl-CAMP 1,900 4.8 
8-Bromo-CAMP 3,900  1.3 
8-Amino-CAMP 6,100 
8-Aminomethyl-CAMP 7,900  6.0 
8-Aminohexylamine-CAMP 8,600 60.0 
8-Aminobenzyl-CAMP >15,000 
cIMP >15,000 30.0 
Insulin  Antagonism in cAMP  Analog-stimulated  Cells 15783 
most potent in adipocytes, but of intermediate potency in 
hepatocytes. 
Correlation of Analog 150 Values for Phosphodiesterase with 
Actual Analog  Hydrolysis-The phosphodiesterase I50 value of 
cAMP analogs was assumed to represent competitive inhibi- 
tion of [3H]cAMP hydrolysis. However, it was possible that 
some analogs were either  acting as noncompetitive inhibitors 
or binding to  the hydrolytic site  without being hydrolyzed. It 
was therefore  important to determine if the analogs were in 
fact being hydrolyzed. Since few  of the analogs commonly in 
use are radioactively labeled, an alternative method was used 
to determine  direct analog hydrolysis. The concentration of 
several analogs was measured before and after incubation 
with the low K ,  phosphodiesterase isolated from rat fat pads. 
Analog concentration was determined using a  standard curve 
for protein kinase activation with each analog tested. As a 
control, hydrolysis of unlabeled cAMP in  this procedure was 
compared with hydrolysis of [3H]cAMP in  the  standard phos- 
phodiesterase assay. The  rates of hydrolysis using the two 
procedures were in good agreement. Fig. 1 shows a typical 
time course of hydrolysis using two cAMP analogs tested by 
this technique. 8-Bromo-CAMP and 8-thioparachlorophenyl- 
cAMP were incubated with the adipose tissue phosphodies- 
terase at 17 and 22 p ~ ,  respectively. These are near the 
respective analog 150 concentrations  (Table 11). Under these 
conditions, about 40% of 8-bromo-CAMP and about 25% of 
8-thioparachlorophenyl-CAMP were hydrolyzed in 30 min. 
Several other  cAMP analogs were also tested at concentra- 
tions at or near  their Is0 values after  a 30-min incubation with 
the phosphodiesterase (data not shown). 8-Amino-, 8-amino- 
methyl-, and 8-thiomethyl-CAMP were also significantly hy- 
drolyzed (20-40%) under  these conditions. However, hydrol- 
ysis of  N‘”benzoy1- and N6-monobutyryl-CAMP was not read- 
ily detected. 
Under the conditions used in these studies, the rates of 
hydrolysis of these analogs could not be compared to one 
another or to cAMP since they were tested at different con- 
centrations. These experiments nevertheless demonstrated 
that some analogs do serve as  substrates for the phosphodi- 
esterase,  albeit at higher concentrations than are required for 
cAMP hydrolysis. For  all analogs tested, hydrolyzable analogs 
(Footnote  b  in  Table 11) have relatively low 150 values, and 
nonhydrolyzable analogs (Footnote  c  in  Table 11) have rela- 
tively high 150 values. The analog 150 values for the phospho- 
diesterases from both cell types were in good agreement 
(Table I1 and Fig. 4). Only the 150 values for N6-benzoyl- and 
I I I I 
0 10 20 30 40 50 
Phosphodiesterase  Incubation  Time (minutes) 
FIG. 1. Time  course  for  the  direct  hydrolysis  of cAMP ana- 
logs by  the  low K ,  phosphodiesterase  from  rat  adipose tissue. 
Analog hydrolysis was determined as described under  “Experimental 
Procedures.” Eachpoint represents the mean of duplicate incubations 
in a typical experiment. a-S-pClph-cA, 8-thioparachlorophenyl- 
CAMP; a-Br-cA, 8-bromo-CAMP. 
N6-carbamoylpropyl-CAMP differed slightly for the phospho- 
diesterases from the two cell types. 
The Effect of Insulin on Hormone- and CAMP Analog- 
stimulated Responses in Adipocytes and Hepatocytes-Before 
the effects of insulin on analog-stimulated cell responses were 
investigated, control experiments were carried out with sev- 
eral  concentrations of epinephrine in adipocytes or glucagon 
in hepatocytes in the presence and absence of a series of 
insulin concentrations  (data  not shown). Insulin (0.1-10  nM) 
inhibited epinephrine-stimulated lipolysis 90-100% when the 
lipolytic effect was less than 50% of a maximal response. 
When lipolysis was stimulated 70-80% of the maximum (1 
p~ epinephrine),  insulin (0.1-1  nM) inhibited glycerol release 
by only 70-80%.  At this higher level of stimulation, insulin 
at 10 nM was less effective as  a lipolytic antagonist (50-60% 
inhibition). This biphasic insulin  inhibition of epinephrine- 
stimulated lipolysis is in agreement with previously published 
data (2). Since a maximal insulin inhibition at all levels of 
epinephrine  stimulation was observed by 1 nM insulin, this 
concentration was chosen as  a  potential  antagonist to analog- 
stimulated lipolysis. 
Similar experiments were carried out in the presence or 
absence of insulin with glucagon-stimulated hepatocytes. 
When phosphorylase activity was stimulated to about 70% of 
the maximum (0.1-1.0 nM glucagon), insulin (0.01-10 nM) 
caused a  concentration-dependent decrease in phosphorylase 
activity. A maximal inhibition of  70-80%  was seen with 
approximately 6 nM insulin. This concentration of insulin 
was used in experiments where the effects of insulin on 
analog-stimulated hepatocytes were investigated. 
It was previously shown that insulin blocks exogenous 
CAMP-stimulated lipolysis or glucose production in adipo- 
cytes (2) and hepatocytes (23), respectively. In this study, 
insulin was tested as a potential antagonist using a large 
number of cAMP analogs as agonists. Hormone and cAMP 
analog concentration curves were generated in  the presence 
and absence of insulin for hepatocyte glycogenolysis  (Fig. 2) 
and adipocyte lipolysis (Fig. 3). Five representative analog 
concentration curves for each cell type are shown. In both 
cell types, responses stimulated by some analogs, but not 
others, were sensitive to insulin inhibition. Responses to 
analogs such as  8-thioethyl-, %amino-, and 8-bromo-CAMP 
in adipocytes and 8-thioethyl-, 8-thioisopropyl-cAMP, and 
cIMP  in hepatocytes were sensitive to inhibition by insulin. 
In  both cell types, responses to N6-benzoyl- and  N6-mono- 
butyryl-CAMP  were resistant to insulin inhibition. The  data 
in  Table I1 for insulin inhibition was  compiled  from concen- 
tration curves like those in Figs. 2 and 3 using 20 cAMP 
analogs in adipocytes and 13 analogs in hepatocytes. The per 
cent  insulin  inhibition was determined from the region of the 
analog concentration curves where insulin causes the greatest 
inhibition. In adipocytes, insulin was most effective at inhib- 
iting lipolysis when the analog-stimulated glycerol release was 
30-60%  of the maximal response. In hepatocytes, insulin was 
most effective when phosphorylase was stimulated 20-40%  of 
the maximum. It can be seen that,  in general, analog-stimu- 
lated responses, which  were sensitive or resistant to insulin 
inhibition  in adipocytes, were the same in hepatocytes. There 
were  two primary exceptions to  this generalization. The re- 
sponse to 8-thioisopropyl-CAMP was blocked by insulin in 
adipocytes, but  not  in hepatocytes. The effect of N6-carba- 
moylpropyl-CAMP  was not  inhibited by insulin in adipocytes, 
but was inhibited  in hepatocytes. 
It should be pointed  out that  the effect of insulin on analog- 
stimulated responses should not be due to differential analog 
penetration of the cell membranes since all insulin effects are 
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TABLE I1 
Comparison of insulin effects with CAMP analog 150 values for phosphodiesterases 
Adipocyte  Hepatocyte 
Cyclic  nucleotides 
inhibition 
Insulin 










































































































Cyclic nucleotides hydrolyzed by the adipocyte phosphodiesterase when tested at their I,, concentration. 
Cyclic nucleotides not hydrolyzed  by the adipocyte  phosphodiesterase when tested at their I50 concentration. 
compared at  equipotent  concentrations of analogs. Therefore, 
one would not expect a correlation between the effects of 
insulin  on analog-stimulated responses and  the butanol/water 
partition coefficient of the analog (32), and none was apparent 
(data  not shown). 
There are several points of interest to the differential 
insulin  inhibition of analog-stimulated responses in these cell 
types (Table I1 and Fig. 4). The responses generated by 
analogs which have modifications at C-8 of the adenine  ring 
were generally inhibited by insulin if the derivative was not 
bulky and/or hydrophobic. For  instance, lipolytic responses 
to 8-amino- and 8-aminomethyl-CAMP were inhibited 70- 
90%, but responses to analogs with bulky substituents, such 
as 8-aminohexylamino- and 8-aminobenzyl-CAMP,  were not 
inhibited significantly by insulin. Likewise, lipolytic responses 
generated by 8-thioethyl- and 8-thiomethyl-CAMP were 
blocked by insulin (75-90%). However, lipolytic responses 
stimulated by 8-thioisopropyl-, 8-thiobenzyl-, and 8-thiopar- 
anitrobenzyl-CAMP were inhibited by insulin by  60, 35, and 
15%, respectively. These same generalizations were true when 
phosphorylase activation was analyzed. At least two excep- 
tions to  the above generalization were  recognized. The lipo- 
lytic response of 8-thioparachlorophenyl-CAMP, containing  a 
relatively bulky group, was inhibited by insulin while 8- 
hydroxy-CAMP, containing  a relatively non-bulky group, was 
not. Although fewer N6 analogs were studied in the  intact 
cells, responses to these analogs were generally not  inhibited 
by insulin. The exceptions to this  are the adipocyte response 
to  N'dmethyl-  and 6-thiomethyl-CAMP and  the hepatocyte 
response to N6-carbamoylpropyl-CAMP. 
Further  studies were designed to find an explanation for 
the discriminative insulin  inhibition of responses to cAMP 
analogs. It was reasoned that if insulin action on lipolysis and 
glycogenolysis was due to stimulation of phosphodiesterase 
activity, insulin would only inhibit  those responses generated 
by analogs which were hydrolyzed by phosphodiesterase. 
Therefore, the effects of insulin on analog-stimulated re- 
sponses were correlated with the analog 150 value for the low 
K, phosphodiesterases from adipocytes and hepatocytes (Fig. 
4). The top and bottom panels of  Fig. 4 represent hepatocyte 
and adipocyte experiments, respectively. The height of each 
bar represents the analog 150 value for the phosphodiesterase 
isolated from the each cell type..The analog Iso is defined as 
the concentration of analog required to cause a half-maximal 
inhibition of cAMP hydrolysis by the respective phosphodies- 
terases using 0.1 ~ L M  [3H]cAMP as substrate. Analogs were 
arbitrarily divided into two general categories. Insulin-sensi- 
tive analog responses (Fig. 4, striped  bars) were inhibited by 
insulin by 260% in adipocytes and 230% in hepatocytes. 
Insulin-resistant analog responses were inhibited  little, if any, 
by insulin. For example, insulin inhibited analog-stimulated 
responses in hepatocytes and adipocytes to 8-bromo- and 8- 
thioparachlorophenyl-CAMP, both of which had relative low 
phosphodiesterase Im values (Fig. 4 and  Table 11) and were 
susceptible to phosphodiesterase hydrolysis (Fig. 1). Insulin 
did not  inhibit analog-stimulated responses in either cell type 
to N'-benzoyl- and N6-monobutyryl-CAMP, both of which 
had relatively high 150 values (Fig. 4 and  Table 11), and were 
not  apparently hydrolyzable. 8-Thiobenzyl-, S-thioparanitro- 
benzyl-, and N6-carbamoylmethyl-CAMP were not included 
since these analog responses were only weakly inhibited by 
insulin (Table 11). There was clearly a strong correlation 
between the 150 value for an analog and  its responsiveness to 
insulin  inhibition  in  both cell types. Although the correlation 
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FIG. 2. The effects of  insulin  on ‘“t -IN- 
hormone-  and  CAMP analog-stimu- 14 
lated  phosphorylase  activation  in - 
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of hormone or CAMP analog and assayed IO 10 Id IO 3 x I d  Io- 3 x IO’ 
for glycerol release as a measure of lipol- ; 
ysis as described under “Experimental g Iz 
Procedures.” Dose-response curves in 5 
the presence and absence of insulin were IO 
determined for each cAMP analog on a 
three or more different adipocyte prep- 
arations. Typical experiments are rep- p 
resented. INS, insulin. 
+ I N S  
Epinephrine ( M i  8-ThioethyI-cAMP(M) 
3 ~ 1 6 ~  Id3 3.10 
N“-Benzoyl-CAMP (M) N6.-8utyryl-cAMP (M) 
I d  
8-Amino-CAMP [M)  
I 2 I  10 
was unmistakable, it was not perfect.  8-Thioisopropyl-CAMP 
had a similar 15,, value  for the phosphodiesterase from both 
cell types, but  its response  was inhibited by insulin in adipo- 
cytes and not in hepatocytes. In hepatocytes, N‘-carbamoyl- 
propyl-CAMP had a relatively low Iso value and  its response 
was inhibited by insulin, while in adipocytes this analog had 
a higher Iso  value and  its response was not inhibited by insulin. 
Although in both cell types there was a strong correlation 
between the effects of insulin on cAMP analog-stimulated 
responses in both cell types and the phosphodiesterase 
values, this did not completely  rule out the possibility that 
insulin acted on the protein kinase. This appeared to be a 
possibility in adipocytes  because there was a vague correlation 
between the sensitivity of cAMP analog effects to insulin 
antagonism and  the apparent affinity of analogs on adipocyte 
type I1 protein kinase (37). Further experiments were there- 
fore carried out to correlate the hepatocyte  responsiveness to 
insulin and the cAMP  analog  specificity  for  hepatocyte type 
I and type I1 protein kinases. For this evaluation, the apparent 
K ,  values  for  cAMP  analog activation of protein kinase iso- 
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FIG. 4. Correlation of hepatocyte and adipocyte low K,,, 
phosphodiesterase 160 values with the effect of insulin on 
analog-stimulated cell responses. The effect of insulin on hepa- 
tocyte phosphorylase activation (top p a w l )  and adipocyte lipolysis 
(bottom panel) was determined for each cAMP analog as illustrated 
in Figs. 2 and 3. Cell responses to cAMP analogs which were not 
inhibited by insulin are shown by open bars, and responses which 
were inhibited by insulin (230% in hepatocytes and 260% in adipo- 
cytes) are shown by striped bars. The  extent of insulin inhibition was 
determined at agonist concentrations eliciting 30-50% of a maximal 
response. The height of each bar indicates the 150 value for each 
cAMP analog using the low K,,, phosphodiesterase from each cell type 
as described under  “Experimental Procedures.” g-S-pCZph, 8-thiopar- 
achlorophenyl-CAMP; 8-Br, 8-bromo-CAMP; 8-S-CzH5, 8-thioethyl- 
CAMP; 8-SXH3, 8-thiomethyl-CAMP; 8-NH-CH3, 8-aminomethyl- 
CAMP; 8-NH2, 8-amino-CAMP; N‘CONH-P, N6-carbamoylpropyl- 
CAMP; N6(C2H&, N‘-diethylamino-CAMP; 8-S-isoP, 8-thioisopro- 
pyl-CAMP;  N‘Bzl, N6-benzoyl-CAMP; 8-NH-Ben, 8-aminobenzyl- 
CAMP; N6-Bt, N6-monobutyryl-CAMP; 8-AHA, 8-aminohexylamino- 
CAMP. 
zymes (concentration of cyclic nucleotide required for half- 
maximal activation)  are expressed as  a relative value or K2 
[K, (cAMP)/K, (cyclic nucleotide)]. Consequently, values 
greater than or less than one indicate that  the  test compound 
is superior or inferior, respectively, to CAMP. Hepatocytes 
were chosen for  these  studies because they were much more 
sensitive than adipocytes to cAMP analog stimulation, and 
therefore more cAMP analogs which were poor activators of 
protein kinases could be tested. This was particularly true of 
cIMP which was a poor lipolytic agent, for reasons previously 
described (32). This analog was an effective glycogenolytic 
agent, albeit a t  high concentrations (Fig. 2). Furthermore, 
hepatocytes were chosen because they  contain  both  type I and 
type I1 protein kinases. It is readily apparent  in Fig. 5 that no 
correlation existed between the IC: of either  type I or type I1 
protein kinases and  the effect of insulin on hepatocyte phos- 
phorylase. For example, insulin blocked the responses to 
cIMP (low K2 for both isozymes), 8-bromo-CAMP (interme- 
diate K2 for both isozymes), and 8-thioparachlorophenyl- 
CAMP (high K2 for both isozymes). Conversely, responses to 
analogs which had  either low or intermediate K: values were 
not blocked by insulin. 
DISCUSSION 
Cyclic nucleotide analogs act on intact cells by crossing the 
cell membrane and  activating the CAMP-dependent protein 
kinases. The predominant, if not  the only, effect of all  tested 
cAMP analogs is directly on the CAMP-dependent protein 
kinase (32). This is supported by studies using cAMP analogs 
which selectively bind to one or the other of two intrasubunit 
cyclic nucleotide-binding sites on the regulatory subunit (40). 
Since these sites interact with positive cooperativity (40), 
addition of a combination of two analogs, one selective for 
one site  and the second for the  other site, causes a synergistic 
activation of the protein kinase (32, 40). In all respects, the 
behavior of site-selective cAMP analog combinations on the 
cooperativity of binding and activation of purified protein 
kinase is equivalent to the behavior of the same analog 
combinations on protein kinase-mediated metabolic re- 
sponses in intact cells (32, 39). 
Since the low K,,, phosphodiesterase from these two cells 
have been shown to be stimulated by insulin, this enzyme is 
a logical candidate for the observed discriminative insulin 
action. For the vast majority of the analogs tested  in  both cell 
types, insulin blocks the responses to analogs with relatively 
low Ibo values for phosphodiesterase but does not block the 
cell responses to analogs with relatively high 150 values. The 
simplest interpretation of these  results  is that insulin blocks 
the cell responses only if the analogs are relatively hydrolyz- 
able. To test  the assumption that a low 150 value is correlated 
with analog hydrolyzability, a method has been developed 
using the CAMP-dependent protein kinase to directly measure 
disappearance of the analog following hydrolysis. The disad- 
vantage of this method is  that  it measures substrate disap- 
pearance rather  than product formation. However, this 
method has a t  least two advantages over previous methods 
which measured analog hydrolysis by phosphate release or 
paper chromatography (41). First, very low levels of cAMP 
analog can be used ( 2 5  nM) compared to much higher con- 
centrations (-1 mM) required by the previous methods. Sec- 
ond, because of the sensitivity of protein kinase, very small 
changes in analog concentration  can be detected. Five analogs 
which have been tested for direct phosphodiesterase hydrol- 
ysis have relatively low 150 values and  are shown to be hydro- 
lyzed. The responses to these same analogs are  inhibited by 
insulin. Analogs such as N6-benzoyl- and  N6-monobutyryl- 
cAMP have higher 150 values and are not hydrolyzed. The 
responses to these analogs are  not  inhibited by insulin. Insulin 
inhibition of responses to only those analogs with low 150 
values (hydrolyzable analogs) suggests that  the activation of 
the phosphodiesterase is an important mechanism of insulin 
action. The differences in insulin inhibition do not appear to 
be due to analog effects on protein kinase since no correlation 
is found between the K2 for the hepatocyte protein kinase 
isozymes and  the effects of insulin on hepatocyte phospho- 
rylase. 
Although low Iso values are well correlated with analog 
hydrolysis for the analogs tested, this relationship will not 
necessarily hold for all analogs with low 150 values. For  in- 
stance, if an analog readily binds to  the hydrolytic site of the 
phosphodiesterase but  is  not hydrolyzed, a low 150 value could 
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FIG. 5. Correlation of hepatocyte 
type I and type I1 protein  kinase KL 
values with the effect of insulin on 
analog-stimulated phosphorylase 
activation. The effect of insulin on  he- 
patocyte phosphorylase activation was 
determined as described in Fig. 2. The 
height of each bar indicates the Kb value 
for each cAMP analog using partially 
purified hepatocyte type I and type I1 
protein kinase as described under “Ex- 
perimental Procedures.” The Kb is de- 
fined as the apparent KO of cAMP (type 
I, 130 nM; type 11,90 nM) divided by the 
apparent K, for cAMP analog. Abbrevi- 
ations are indicated in Fig. 4. 
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be obtained. Analogs such as 8-thioparanitrobenzyl- and 8- 
thiobenzyl-CAMP, whose responses in adipocytes are mini- 
mally inhibited by insulin, may fit this classification. 150 values 
have been determined for N6-benozyl- and N‘-monobutyryl- 
CAMP, yet hydrolysis is not detected when tested at or near 
their 150 values. This suggests that they inhibit [3H]cAMP 
hydrolysis by a noncompetitive mechanism, or that they  bind 
to  the hydrolytic site, block [3H]cAMP hydrolysis, but  are  not 
hydrolyzed themselves. Although direct hydrolysis studies 
were conducted using only the adipocyte phosphodiesterase, 
a comparison of phosphodiesterase 150 values from both cell 
types suggests that  the enzymes are similar, but probably not 
identical. 
Consideration was  given to several possible artifacts which 
could be responsible for these results. The discriminative 
action of insulin does not  appear to be due to  an elevation of 
endogenous cAMP resulting from inhibition of phosphodies- 
terase by some analogs but  not others.  A  recent  study  had 
demonstrated that cAMP analogs actually decrease endoge- 
nous cAMP levels (42). It could possibly be argued that cAMP 
analogs cause Ca2+ mobilization and  alter hepatocyte phos- 
phorylase activity by stimulating phosphorylase kinase. It has 
been shown that high concentrations of glucagon (lo-’ M), 
which fully activate  protein kinase and phosphorylase, raise 
intracellular Ca2+, but possibly via a  protein kinase mecha- 
nism (43). These conditions are  in  contrast to  the conditions 
used in the present  studies where optimal  insulin  inhibition 
is observed when phosphorylase is  activated by only 20-40% 
of the maximal response. Nonspecific alterations of intracel- 
lular cAMP analogs by mechanisms other  than phosphodies- 
terase hydrolysis have been studied for only some analogs 
(44). However, that such  a mechanism could be responsible 
for these  results seems unlikely due to  the diversity of cAMP 
analogs within the two groups whose responses are blocked, 
or not blocked, by insulin. 
Recently, studies of the effects of insulin on hepatocyte 
glucose production stimulated by 8-bromo-CAMP (23) and 
adipocyte lipolysis stimulated by 8-thiomethyl- and 8-thio- 
isopropyl-CAMP have been reported (24). From these experi- 
ments  and others, and  in  contrast  to  the conclusions of the 
present paper, the  authors concluded that insulin does not act 
through phosphodiesterase activation. The results  in the pres- 
ent paper, using these same three cAMP analogs in  the same 
cell types, are  in agreement, i.e. insulin blocks these cAMP 
analog-stimulated responses. However, the interpretations of 
these  results  are completely different. Part of this  is due to 
the use of a large number of cAMP analogs in  both cell types 
in  the present paper, and indeed some analog responses are 
not  inhibited by insulin. The prevailing view in  the literature 
that many cAMP analogs are poorly hydrolyzed is correct. 
Compared to CAMP, most analogs are relatively poor sub- 
strates for the phosphodiesterase. However, in the present 
study, several cAMP analogs with low 150 values are shown to 
be  hydrolyzed using a sensitive, direct method. 
Several studies have shown that cell responses to isobutyl- 
methylxanthine and other phosphodiesterase inhibitors are 
inhibited by insulin (2, 23, 24, and  this study). It has been 
argued that retention of an inhibitory effect of insulin in  the 
presence of phosphodiesterase inhibition suggests that insulin 
does not  act through phosphodiesterase (23,  24). While this 
seems logical, the differential action of insulin in cAMP 
analog responses suggests that  this conclusion requires recon- 
sideration. Although isobutylmethylxanthine has  a low Ki for 
phosphodiesterase inhibition (16), the inhibition is likely not 
complete, suggesting that only a small amount of phosphodi- 
esterase activity is required for the insulin effect. This is 
consistent with the observation that some analogs require 
concentrations 20-100 times greater than cAMP for hydrol- 
ysis, yet insulin  still blocks the response to these analogs. It 
is possible that insulin as well as  agents which elevate endog- 
enous cAMP stimulate  a common (16, 45) or a different (46) 
phosphodiesterase. A recent study has suggested that the 
elevation of cAMP and  the activation of the protein kinase 
result in a feedback inhibition to “dampen” the rise in cAMP 
(42). This system may act in concert with a possible insulin 
stimulation of phosphodiesterase. Although this  has  not been 
proved, it is consistent with results that show endogenous 
cAMP must be elevated before insulin  can lower the cyclic 
nucleotide. 
In  the course of these studies, a number of observations 
have been made on  the cAMP analog potency in  intact cells. 
All analogs used in  the present  study can fully activate protein 
kinase in vitro. Cyclic nucleotide analogs can be good in vivo 
protein kinase agonists if they reach effective concentrations 
in the cell. The principles of analog efficacy appear to be 
based on fundamental pharmacological principles of drug 
15788 Insulin Antagonism in CAMP Analog-stimulated Cells 
action which have been shown to be applicable to analog 
action on adipocyte lipolysis (32). Therefore, analog efficacy 
depends not only on the concentration of the analog required 
to activate the protein kinase (apparent K,, e.g. agonist po- 
tency), but also on the partitioning characteristics of the 
analog (partition coefficient, e.g. an indication of lipid/water 
solubility) and  the susceptibility of the analog to hydrolysis 
by phosphodiesterases (I5o and analog hydrolysis, e.g. route of 
elimination). All of these characteristics have  usually not been 
dealt with in previous reports of cAMP analog effects in  intact 
tissues. Comparison of the efficacy of cAMP analogs in adi- 
pocytes and hepatocytes in this paper also suggests that  the 
porosity of the cell membrane and  the lipid content of the cell 
may also be important. 
The hepatocyte response is 100-1000 times more sensitive 
to cAMP analog stimulation than the adipocyte response. 
Since there  are only minor differences in analog specificity of 
the protein kinases (this study, 37) and low K ,  phosphodies- 
terase between these cell types, other factors are probably 
responsible  for these differences. Perhaps a different level of 
phosphodiesterase activity, rather than a difference in speci- 
ficity of this enzyme, could account for the differences. A 
second possibility may  be a relative “leakiness” of hepatocyte 
membranes. Another factor could  be the high  lipid to cyto- 
plasm ratio of adipocytes compared to hepatocytes. Analogs 
with high partition coefficients  may not readily reach effective 
concentrations in  the cytoplasm because they become trapped 
in  the lipid of the adipocytes.  Mooney et al. (47) have  sug- 
gested that compartmentalization of enzymes  involved in  the 
lipolytic response may  provide a second permeability barrier 
to  the analog.  Although the reasons for these potency differ- 
ences are not known, one or more of these factors are probably 
involved. In any case, other cell types will presumably respond 
differently, and it may be possible to use certain cAMP 
analogs in the whole organism to selectively stimulate some 
cell types and not others. 
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